Nice said the price the health service is being asked to pay for the drug is too high for the benefit it may provide to patients A drug used to treat women with ovarian cancer has been rejected as too expensive for the NHS by health officials. Olaparib was given to women with BRCA1 or BRCA2 mutations of the disease, but the National Institute for Health and Care Excellence said the price the health service is being asked to pay for it is too high for the benefit it may provide to patients.

Click here to read original article